Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Oncolytics Biotech Inc (TSX: ONC )

1.290 -0.020 (-1.53%)
Streaming Delayed Price Updated: 1:01 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,304
Open 1.260
Bid (Size) 1.280 (22)
Ask (Size) 1.300 (2)
Prev. Close 1.310
Today's Range 1.260 - 1.290
52wk Range 1.060 - 3.550
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent... 
Via FinancialNewsMedia
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting
Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant... 
Via FinancialNewsMedia

Performance

YTD
-26.70%
-26.70%
1 Month
-12.84%
-12.84%
3 Month
-35.18%
-35.18%
6 Month
-28.33%
-28.33%
1 Year
-62.72%
-62.72%

More News

Read More
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
Via FinancialNewsMedia
Exposures COVID-19
Promising Results Continue to Develop Optimism in Fight Against Cancers
Via FinancialNewsMedia
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Via FinancialNewsMedia
Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer
Via FinancialNewsMedia
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer
Via FinancialNewsMedia
Billions Flowing into Cancer Immunotherapy as Market Responds to Impressive Market Potential
Via FinancialNewsMedia
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Via FinancialNewsMedia
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
Via FinancialNewsMedia
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Oncolytics Biotech® Provides Enrollment Update on Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium
Via FinancialNewsMedia
Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer
Via FinancialNewsMedia
Topics Death
Exposures Death
Breast Cancer Treatment Advancements Emerge After New Study Finds Global Deaths Increased in 2019
Via FinancialNewsMedia
Topics Death
Exposures Death
Promising Developments in Breast Cancer Treatments Ahead in 2022
Via FinancialNewsMedia
New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024
Via FinancialNewsMedia
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Via FinancialNewsMedia
Oncolytics Biotech® Promotes Thomas C. Heineman, M.D., Ph.D., to Chief Medical Officer
Via FinancialNewsMedia
Ongoing R&D Leading to Discovery of More Efficient Therapies for Acute Myeloid Leukemia Therapeutics
Via FinancialNewsMedia
Oncolytics Biotech® Announces the Presentation of Preclinical Data Demonstrating the Synergistic Anti-Leukemic Effects of Pelareorep Combined with Azacitidine at the 2021 American Society of Hematology Annual Meeting
Via FinancialNewsMedia
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Big Trend Occurring in Triple-Negative Breast Cancer Treatment Is The Shift Towards Combination Therapy
Via FinancialNewsMedia
Oncolytics Biotech® Presents Positive Interim Safety Update from Phase 2 Triple-Negative Breast Cancer Trial at the 2021 San Antonio Breast Cancer Symposium
Via FinancialNewsMedia
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
Via FinancialNewsMedia
Global Metastatic Cancer Treatment Market Size Is Forecasted To Reach $111.16 Million By 2027
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.